ライフサイエンスコーパス: treatment-responsive

1 spects of antisocial adjustment appear to be treatment responsive.

2 ve symptoms of schizophrenia are enduring or treatment-responsive.

3 haryngeal squamous cell carcinoma (OPSCC) is treatment-responsive.

4 stic biomarker that can discriminate between treatment responsive and resistant tumor models.

5 Compared to controls, treatment responsive and treatment-resistant participant

6 (1 year later), when 35 were categorized at treatment-responsive and 15 as treatment-resistant.

7 roduction, were compared in 16 patients with treatment-responsive and 16 with treatment-resistant Lym

8 bolic response to a neuroleptic challenge in treatment-responsive and nonresponsive schizophrenic pat

9 t mechanisms underlie the pathophysiology of treatment-responsive and treatment-resistant schizophren

10 ociate with LE that is often paraneoplastic, treatment responsive, and has a tendency to relapse.

11 ral prefrontal cortex when compared to those treatment-responsive, and with bilateral dorsolateral pr

12 pes), whereas only 5 of the 16 patients with treatment-responsive arthritis had reactivity with these

13 in A (OspA), but TCL from four patients with treatment-responsive arthritis only rarely recognized th

14 etween patients with treatment-resistant and treatment-responsive arthritis was in reactivity with N-

15 andidiasis were paired with controls who had treatment-responsive candidiasis and who had been observ

16 sentation were independently associated with treatment-responsive causes of RPD after controlling for

17 mized to recognize patients with potentially treatment-responsive causes of RPD early in the diagnost

18 , and sTREM2 identified the 44 patients with treatment-responsive causes of RPD with 89% accuracy.

19 y and to recognize patients with potentially treatment-responsive causes of RPD.

20 eliably identified patients with potentially treatment-responsive causes of RPD.

21 of whom 86 patients (55.5%) had potentially treatment-responsive causes.

22 ate that AAG patients may also show signs of treatment-responsive cognitive impairment.

23 es significantly associated with lower-stage/treatment-responsive CTCL versus higher-stage/treatment-

24 tions, and most often manifests with milder, treatment-responsive disease.

25 eceptor (AMPAR) encephalitis is a severe but treatment-responsive disorder with prominent short-term

26 described a severe, potentially lethal, but treatment-responsive encephalitis that associates with a

27 ers of the NMDAR associate with a severe but treatment-responsive encephalitis.

28 d controlled trial, was profiled to reveal a treatment-responsive gene signature.

29 We demonstrated how these treatment-responsive genes could be translated into a pr

30 Most of the rest of the treatment-responsive genes we categorized as mediators o

31 We discovered approximately 200 treatment-responsive genes, many of them known mediators

32 sting to confirm benefit in this potentially treatment-responsive group is needed.

33 ere compared between treatment-resistant and treatment-responsive groups and related to glutamate.

34 ion over time of patients with complex, less treatment-responsive illnesses.

35 plication, indicating that HIV infection was treatment responsive in the DRAGA mice.

36 DG-PET biomarker strategy to identify mGluR2 treatment-responsive individuals.

37 ent-resistant depression (TRD) compared with treatment-responsive major depressive disorder (trMDD).

38 TRD vs. non-major depressive disorder (MDD), treatment responsive MDD (trMDD) vs. non-MDD, and TRD vs

39 Results indicate that HCO3(-) treatment responsive metabolomic changes depend on the H

40 Treatment-responsive Mtm1 p.R69C gastrocnemius muscles d

41 tment response: treatment resistant (n=5) or treatment responsive (n=4).

42 tiation (N=45), patients whose symptoms were treatment responsive (N=40), and patients whose symptoms

43 d with RPD were characterized as potentially treatment-responsive or non-responsive, referencing clin

44 cerbations, those whose asthma might be less treatment responsive, or both might guide treatment sele

45 Treatment-responsive participants showed a negative rela

46 Treatment-responsive participants showed significant sig

47 The mean age of treatment-responsive patients (group 1) was 45.88 +/- 18

48 differences between treatment-resistant and treatment-responsive patients include reductions in grey

49 apacity and prefrontal grey matter volume in treatment-responsive patients with psychosis, and compar

50 management of a non-negligible proportion of treatment-responsive patients.

51 esults suggest that treatment-predictive and treatment-responsive regions may be anatomically differe

52 Sixteen clinically silent, treatment-responsive rejection episodes occurred in 10 r

53 PI3K-alpha (P = 0.04) were downregulated in treatment responsive residual tumors, when compared with

54 AM(3) P), captured 82 of 86 (95.3%) cases of treatment-responsive RPD.

55 in such individuals compared with those with treatment responsive schizophrenia, and healthy controls

56 hypothesis to indicate it can be applied to treatment-responsive schizophrenia only.

57 iagnosis (past or present), individuals with treatment-responsive schizophrenia taking nonclozapine a

58 nt-resistant schizophrenia, 21 patients with treatment-responsive schizophrenia, and 18 healthy contr

59 ant schizophrenia lie along a continuum with treatment-responsive schizophrenia, whereas other differ

60 rived subphenotyping algorithms may identify treatment-responsive subgroups of critically ill patient

61 in retrospective studies, and that the same treatment-responsive subpopulations may cross multiple c

62 ntly higher than the RVI among patients with treatment-responsive symptoms (mean=0.30 [SD=0.02]).

63 h SZ (n=25); NC, treatment-resistant SZ, and treatment-responsive SZ; and 3) NC and SZ treated with t

64 g response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL.

65 Compared to treatment-responsive, treatment-resistant participants s

66 On-treatment, responsive tumours contained abundant granzym